Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15

• Published in: Vaccine Vol. 28; no. 50; pp. 7829 - 7836
• Main Authors: Carvalho, Luciana V, Ruiz, Rita de C, Scaramuzzi, Karina, Marengo, Eliana B, Matos, Jivaldo R, Tambourgi, Denise V, Fantini, Marcia C.A, Sant’Anna, Osvaldo A
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 23-11-2010; Elsevier; Elsevier Limited
• Subjects: Adjuvant; Adjuvants, Immunologic - pharmacology; Adsorption; Allergy and Immunology; Aluminum; Aluminum Hydroxide - pharmacology; Animals; Antibody Formation; Applied microbiology; Biological and medical sciences; Bone marrow; Cells, Cultured; Female; Freund's Adjuvant - pharmacology; Fundamental and applied biological sciences. Psychology; Immune system; Immunization; Immunogenicity; Immunoglobulin G - blood; Immunological memory; Lipids - pharmacology; Lymphocytes; Macrophages - immunology; Medical research; Mice; Microbiology; Nanoparticles; Phagocytosis; Serum Albumin, Bovine - immunology; Silica; Silicon Dioxide - pharmacology; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Immunogenicity; Immunological memory; Adjuvant; Silica; Immunological adjuvant; Inorganic compound
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2010.09.087

Abstract In 2006, the first report of a nanostructured material as adjuvant was described establishing the effectiveness of the ordered mesoporous SBA-15 silica as an immune adjuvant. The present study evaluated the SBA-15 capacity to modulate the immune responsiveness of High and Low responder mice immunized with BSA encapsulated/adsorbed in SBA-15 by the intramuscular or oral route and the adjuvant effect was compared with the responsiveness induced by BSA in aluminum hydroxide salts or emulsified in Incomplete Freund adjuvant. These results demonstrate the ability of the non-toxic SBA-15 nanoparticles to increase the immunogenicity and repair the responsiveness of the constitutively low responder individuals inducing both the IgG2a and the IgG1 isotypes, independently of the immune cell committed and conditioning the low phenotype. This new adjuvant may reveal novel therapeutic targets for immune modulation and vaccine design.